+ Equity
AI usage for efficient biomedical research
Open for applications
AI usage for efficient biomedical research
201-500 employees
Open for applications
+ Equity
201-500 employees
To exponentially increase the speed and quality of life-saving research by empowering scientists with the world's most advanced biomedical artificial intelligence.
Over the past decade, the cost of bringing a drug to market has increased exponentially while the number of drugs approved has stayed stagnant, leading to a decline in research productivity. Through development of AI-assisted software, BenchSci has allowed scientists to rapidly compute data from scientific journals and product catalogues to dramatically reduce these inefficiencies in the R&D process.
The company offers a lateral solution to traditional, manual data analysis to allow for data leveraging and an automated, comprehensive overview of existing relevant research. These methods have made BenchSci a forerunner in the drug development industry; the company's software is used by leading pharmaceutical companies.
BenchSci continually invests in its machine learning technology, and in January 2023 announced the launch of ASCEND, software that extracts experimental evidence from internal and external sources to create commercially available maps of disease biologies, improving the hit rate of drug trials.
Steph
Company Specialist
31% employee growth in 12 months
May 2023
$70.4m
SERIES D
Jan 2022
$46.7m
SERIES C
South Core, Toronto, ON
Founders
Dr. Elvis Wianda
(Chief Data Officer)Obtained a PhD studying Health & Medical Physics at the University of Toronto before joining BenchSci.
Dr. Tom Leung
(CSO)Previously held roles within the University of Toronto as a Research Assistant and Postdoctoral Fellow.
Liran Belenzon
(CEO)Previously co-founded and held role as CEO at companies including Standy and Biz-Coupon. Currently a CDL Associate at Creative Destruction Lab.
Diversity & Inclusion at BenchSci
Share this job
View 4 more jobs at BenchSci